Astria Therapeutics Inc. (ATXS)
5.14
-0.38 (-6.88%)
At close: Apr 03, 2025, 3:59 PM
5.06
-1.56%
Pre-market: Apr 04, 2025, 04:43 AM EDT
-6.88% (1D)
| Bid | 5 |
| Market Cap | 290.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.68 |
| PE Ratio (ttm) | -3.06 |
| Forward PE | -4.05 |
| Analyst | Buy |
| Ask | 5.19 |
| Volume | 188,426 |
| Avg. Volume (20D) | 275,960 |
| Open | 5.26 |
| Previous Close | 5.52 |
| Day's Range | 5.07 - 5.33 |
| 52-Week Range | 5.05 - 12.92 |
| Beta | 0.68 |
About ATXS
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceutical...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2015
Employees 78
Stock Exchange NASDAQ
Ticker Symbol ATXS
Website https://www.astriatx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ATXS stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 425.29% from the latest price.
Stock Forecasts7 months ago
+7.48%
Astria Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
